Diarrhea News and Research

Latest Diarrhea News and Research

FDA conditionally approves first oral treatment for dogs with lymphoma

Today, the U.S. Food and Drug Administration conditionally approved Laverdia-CA1 (verdinexor tablets) to treat dogs with lymphoma, a type of cancer of the lymph nodes and lymphatic system.

11 Jan 2021

Researchers succeed in mapping the structure of virus that causes diarrhea

Researchers at Umeå University in Sweden have for the first time at the atomic level succeeded in mapping what a virus looks like that causes diarrhea and annually kills about 50,000 children in the world.

11 Jan 2021

Researchers demonstrate lab tool that simplifies simulations of the human intestine

Rice University and Baylor College of Medicine researchers have found a way to mimic conditions in intestines, giving them a mechanical model for the real-time growth of bacterial infections.

8 Jan 2021

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

A new preprint research paper appearing on the medRxiv server describes a link between the persistence of neutralizing antibodies against the virus, disease severity, and specific COVID-19 symptoms.

7 Jan 2021

Innovative artistic intervention can help reduce fatal health threat to young African children

The fatal threat from diarrhea and pneumonia to young children in the world's poorer countries can be drastically reduced by using traditional performing arts to encourage mothers to provide youngsters with safe food and water, a new study reveals.

7 Jan 2021

Researchers examine the role of Shiga toxin in the immune system

E. coli food poisoning is one of the worst food poisonings, causing bloody diarrhea and kidney damage. But all the carnage might be just an unintended side effect, researchers from UConn Health report in the 27 November issue of Science Immunology.

7 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Smokers at increased risk of developing symptomatic COVID-19

Smoking is associated with an increased risk of COVID-19 symptoms and smokers are more likely to attend hospital than non-smokers, a study has found.

6 Jan 2021

Study: Antibiotics are not necessary after most endoscopic sinus surgeries

Antibiotics are not necessary for patients after most routine endoscopic sinus surgeries despite the common practice to prescribe them, according to a team led by researchers at Massachusetts Eye and Ear.

6 Jan 2021

Study investigates the total non-healthcare cost of chemotherapy

Chemotherapy for breast cancer costs the UK economy more than £248 million annually, including 'out-of-pocket' personal costs of more than £1,000 per patient - according to new research from the University of East Anglia.

4 Jan 2021

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Preliminary data from the non-powered U.S. Phase 2 study of 40 hospitalized patients shows that orally-administered opaganib was safe, with no material safety differences between opaganib and control arms.

4 Jan 2021

Popular glucose-lowering drug may cause rare diabetes complication in COVID-19 patients

Diabetes is a known risk factor for morbidity and mortality related to COVID-19. In diabetes patients, rare but severe complications, like the potentially lethal condition diabetic ketoacidosis (DKA), can arise when illness or certain conditions prevent cells from receiving enough glucose to fuel their functioning.

28 Dec 2020

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Top-line data from the 270-patient global Phase 2/3 COVID-19 study expected Q1/2021. Top-line data from the 40-patient U.S. Phase 2 study of opaganib in severe COVID-19 expected in the coming days; this non-powered study was designed to evaluate safety and potential identification of preliminary efficacy signals in support of the global Phase 2/3 study of opaganib.

23 Dec 2020

Anti-diarrhea drug triggers cell death in glioblastoma cells

In cell culture, loperamide, a drug commonly used against diarrhea, proves effective against glioblastoma cells. A research team at Goethe University has now unraveled the drug’s mechanisms of action of cell death induction and – in doing so – has shown how this compound could help attack brain tumors that otherwise are difficult to treat.

22 Dec 2020

Research may lead to better treatment and vaccines for Ebola, COVID-19

In the midst of a global pandemic with COVID-19, it's hard to appreciate how lucky those outside of Africa have been to avoid the deadly Ebola virus disease.

21 Dec 2020

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

Today, the U.S. Food and Drug Administration approved Tagrisso (osimertinib) as the first adjuvant treatment for patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation.

18 Dec 2020

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Today, the U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer.

18 Dec 2020

Scientists identify new Salmonella proteins

Salmonella are bacteria that can cause food poisoning with severe diarrhea. If they penetrate from the intestine into the blood system, this can lead to sepsis, life-threatening inflammatory reactions in the entire organism.

16 Dec 2020

RedHill Biopharma announces promising preliminary results from opaganib study

TEL AVIV, Israel and RALEIGH, NC, December 15, 2020, RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced promising preliminary results from a preclinical study with opaganib.

15 Dec 2020

Combination therapy places no greater burden on early-stage breast cancer patients

Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, new research by Dana-Farber/Brigham and Women's Cancer Center investigators shows.

10 Dec 2020

Diarrhea News and Research

Latest Diarrhea News and Research

FDA conditionally approves first oral treatment for dogs with lymphoma

Researchers succeed in mapping the structure of virus that causes diarrhea

Researchers demonstrate lab tool that simplifies simulations of the human intestine

Link between fever, diarrhea, severe COVID-19, and persistent anti-SARS-CoV-2 antibodies

Innovative artistic intervention can help reduce fatal health threat to young African children

Researchers examine the role of Shiga toxin in the immune system

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Smokers at increased risk of developing symptomatic COVID-19

Study: Antibiotics are not necessary after most endoscopic sinus surgeries

Study investigates the total non-healthcare cost of chemotherapy

P2 COVID-19 study shows no material safety differences between opaganib and control arms

Popular glucose-lowering drug may cause rare diabetes complication in COVID-19 patients

Phase 2/3 COVID-19 study evaluates safety, potential identification of preliminary efficacy signals

Anti-diarrhea drug triggers cell death in glioblastoma cells

Research may lead to better treatment and vaccines for Ebola, COVID-19

FDA approves first adjuvant treatment for patients with non-small cell lung cancer

FDA approves first oral drug for treating adult patients with advanced prostate cancer

Scientists identify new Salmonella proteins

RedHill Biopharma announces promising preliminary results from opaganib study

Combination therapy places no greater burden on early-stage breast cancer patients

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Diarrhea News and Research

Latest Diarrhea News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in